Merrimack Pharmaceuticals Named New Long Idea At Seven Corners Capital, Firm Sets $10.50 Price Target And Sees 84% Upside; Calls Stock ' Relatively Safe Pharma Play with Significant Upside'
Benzinga Newsdesk